Humoral and Cellular Aspects of Amyloid Disease: Present Status1

2015 ◽  
pp. 250-276
Author(s):  
Morton A. Scheinberg ◽  
Jeffrey R. Wohlgethan ◽  
Edgar S. Cathcart
Keyword(s):  
Amyloid Disease ◽  
Disease Present

scholarly journals ctDNA Clearance and Radiographic Resolution of Disease in Response to Dual Checkpoint Inhibition in Metastatic Microsatellite Stable Colorectal Cancer with a High Tumor Mutation Burden

2021 ◽  
pp. 849-853
Author(s):  
Charles J. Schneider ◽  
Michael Krainock ◽  
Allyson Koyen Malashevich ◽  
Meenakshi Malhotra ◽  
Perry Olshan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Lymph Node ◽  
Ct Scan ◽  
Circulating Tumor Dna ◽  
Therapeutic Benefit ◽  
Tumor Mutation Burden ◽  
Early Treatment Response ◽  
Mutation Burden ◽  
Disease Present

Immunotherapy (IO) has increasingly been demonstrated to provide therapeutic benefit to patients with metastatic colorectal cancer (mCRC). However, only a subset of mCRC tumors respond to IO. Monitoring response with tumor biomarkers like carcinoembryonic antigen (CEA) has been challenging in patients with microsatellite stable (MSS) mCRC due to low expression of CEA (CEA/lo). Noninvasive blood-based biomarkers such as circulating tumor DNA (ctDNA) can inform early treatment response and augment radiographic monitoring. We describe a case study of a patient with chemotherapy-refractory CEA/lo MSS mCRC, with metastatic disease present in a cardiophrenic lymph node. The patient was given 2 cycles of combination IO (ipilimumab/nivolumab). Response was monitored by ctDNA using a multiplex PCR next-generation sequencing assay, CEA, and CT scan. After IO administration, ctDNA levels rapidly declined, becoming undetectable. This was concurrent with radiographic resolution of the lymph node metastasis. Serial monitoring of CEA during this same period was uninformative, with no significant changes observed. Significant decline in ctDNA identified metastatic response to IO in a patient with CEA/lo, MSS mCRC and was concurrently validated by CT scan. This case study provides evidence that ctDNA can be used as a prospective surrogate for radiographic tumor response.

Measuring Disease Modification in Alzheimer's Disease

CNS Spectrums ◽  
2007 ◽  
Vol 12 (S1) ◽  
pp. 11-14
Author(s):  
Jeffrey L. Cummings
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Immunoglobulin A ◽  
Disease Process ◽  
Underlying Disease ◽  
Therapeutic Interventions ◽  
Disease Modification ◽  
Amyloid Disease ◽  
Therapeutic Modalities ◽  
Disease Modifying

AbstractWe appear to be on the brink of a new epoch of treatment for Alzheimer's disease. Compelling evidence suggests that Aβ42 secretion is the triggering event in the pathogenesis of Alzheimer's disease, and that tau aggregation may be an important secondary event linked to neurodegeneration. Prophylactic administration of anti-amyloid agents designed to prevent Aβ accumulation in persons with subclinical disease is likely to be more effective than therapeutic interventions in established Alzheimer's disease. Drug development programs in Alzheimer's disease focus primarily on agents with anti-amyloid disease-modifying properties, and many different pharmacologic approaches to reducing amyloid pathology and tauopathy are being studied. Classes of therapeutic modalities currently in advanced-stage clinical trial testing include forms of immunotherapy (active β -amyloid immunoconjugate and human intravenous immunoglobulin), a γ-secretase inhibitor, the selective Aβ42-lowering agent R-flurbiprofen, and the anti-aggregation agent tramiprosate. Non-traditional dementia therapies such as the HMG-CoA reductase inhibitors (statins), valproate, and lithium are now being assessed for clinical benefit as anti-amyloid disease-modifying treatments. Positive findings of efficacy and safety from clinical studies are necessary but not sufficient to demonstrate that a drug has disease-modifying properties. Definitive proof of disease-modification requires evidence from validated animal models of Alzheimer's disease; rigorously controlled clinical trials showing a significantly improved, stabilized, or slowed rate of decline in cognitive and global function compared to placebo; and prospectively obtained evidence from surrogate biomarkers that the treatment resulted in measurable biological changes associated with the underlying disease process.

Amyloid Disease of the Conjunctiva*

1945 ◽  
Vol 28 (5) ◽  
pp. 486-497 ◽  
Author(s):  
Norma B. Elles
Keyword(s):  
Amyloid Disease

Amyloid Disease with Hypertension

1950 ◽  
Vol 242 (23) ◽  
pp. 891-894 ◽  
Author(s):  
Samuel E. Leard ◽  
William E. Jaques
Keyword(s):  
Amyloid Disease

Deep Learning-Based Knowledge Extraction From Diseased and Healthy Edible Plant Leaves

2021 ◽  
Vol 12 (2) ◽  
pp. 67-81
Author(s):  
Udit Jindal ◽  
Sheifali Gupta
Keyword(s):  
Neural Network ◽  
Deep Learning ◽  
Plant Disease ◽  
Disease Detection ◽  
Edible Plant ◽  
Research Article ◽  
Segmented Images ◽  
Significant Area ◽  
Testing Accuracy ◽  
Disease Present

Agriculture contributes majorly to all nations' economies, but crop diseases are now becoming a very big issue that has to be resolving immediately. Because of this, crop/plant disease detection becomes a very significant area to work. However, a huge number of studies have been done for automatic disease detection using machine learning, but less work has been done using deep learning with efficient results. The research article presents a convolution neural network for plant disease detection by using open access ‘PlantVillage' dataset for three versions that are colored, grayscale, and segmented images. The dataset consists of 54,305 images and is being used to train a model that will be able to detect disease present in edible plants. The proposed neural network achieved the testing accuracy of 99.27%, 98.04%, and 99.14% for colored, grayscale, and segmented images, respectively. The work also presents better precision and recall rates on colored image datasets.

Sign in / Sign up

Export Citation Format

Share Document